| 23015 |
Ivosidenib |
Tibsovo® |
To be used in combination with azacitidine, as indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy. |
NCPE Assessment Process Complete |
16th December 2025 |
 |
| 23016 |
Ivosidenib |
Tibsovo® |
For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy |
NCPE Assessment Process Complete |
7th March 2025 |
|
| - |
Ixazomib |
Ninlaro® |
In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
Assessment process complete |
18th December 2017 |
|
| - |
Ixekizumab |
Taltz® |
For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. |
Rapid Review Complete |
26th July 2016 |
|
| - |
Ixekizumab |
Taltz® |
For the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies |
Rapid Review Complete |
20th November 2018 |
|
